Abstract Exacerbated production of matrix metalloproteinases (MMPs) is a key event in the progression of osteoarthritis (OA) and represents a promising target for the management of OA with nutraceuticals. In this study, we sought to determine the MMP-inhibitory activity of an ethanolic Caesalpinia sappan extract (CSE) in human OA chondrocytes. Thus, human articular chondrocytes isolated from OA cartilage and SW1353 chondrocytes were stimulated with Interleukin-1beta (IL1b), without or with pretreatment with CSE. Following viability assays, the production of MMP-2 and MMP-13 was assessed using ELISA, whereas mRNA levels of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13 and TIMP-1, TIMP-2, TIMP-3 were quantified using RT-qPCR assays. Chondrocytes were co-transfected with a MMP-13 luciferase reporter construct and NF-kB p50 and p65 expression vectors in the presence or absence of CSE. In addition, the direct effect of CSE on the proteolytic activities of MMP-2 was evaluated using gelatin zymography. We found that CSE significantly suppressed IL1b-mediated upregulation of MMP-13 mRNA and protein levels via abrogation of the NF-kB(p65/p50)-driven MMP-13 promoter activation. We further observed that the levels of IL1b-induced MMP-1, MMP-3, MMP-7, and MMP-9 mRNA, but not TIMP mRNA levels, were down-regulated in chondrocytes in response to CSE. Zymographic results suggested that CSE did not directly interfere with the proteolytic activity of MMP-2. In summary, this study provides evidence for the MMP-inhibitory potential of CSE or CSE-derived compounds in human OA chondrocytes. The data indicate that the mechanism of this inhibition might, at least in part, involve targeting of NF-kB-mediated promoter activation.
degenerated OA cartilage (Saha et al. 1999) as well as in the synovial membranes and synovial fluids of OA patients (Smith et al. 1997; Kubota et al. 1997) . At the cellular level, chondrocytes respond to this cytokine via a cascade of events leading to loss of balance between cartilage anabolism and catabolism, associated with phenotypic modulation and activation of the normally quiescent chondrocytes (Goldring and Marcu 2009; Goldring et al. 2008) . In OA cartilage, IL1b and TNFa co-localize with increased levels of matrix metalloproteinases (MMPs) (Tetlow et al. 2001) , and IL1b was shown to upregulate MMP expression levels in normal human chondrocytes, OA chondrocytes, and chondrosarcoma cells (Tetlow et al. 2001; Fan et al. 2005; Mix et al. 2001 ).
According to their main substrate specificity, proteins of the MMP family can be divided into collagenases (MMP-1, MMP-8, MMP-13), gelatinases (MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10, MMP-11), and membrane type I MMPs . Restriction of the proteolytic activities of MMPs is mediated by endogenous tissue inhibitors of MMPs (TIMPs) (Nagase and Woessner 1999) . MMPs play important roles in physiological processes such as tissue repair, but also become part of destructive disease processes due both to its overexpression and the excessive activation of pro-MMPs into their active forms. Interestingly, a recent study by Little et al. demonstrated that MMP-13-knockout mice were less prone than wild-type mice to develop tibial cartilage structural damage following medial meniscal destabilization surgery in the knee (Little et al. 2009 ). Taken together, MMPs might represent promising targets for therapeutic intervention in OA.
To date, classic therapeutic approaches of OA are still limited to exercise, palliative drugs or surgical intervention. There is growing awareness, however, that nutritional factors can positively influence the maintenance of bone and joint health. Articular cartilage is critically dependent upon the regular provision of nutrients, vitamins, and essential trace elements (Goggs et al. 2005) . Thus, dietary supplementation programs and nutraceuticals might provide long-term benefits to patients with a chronic disease such as OA. In general, the benefits offered by nutraceuticals are based on the lack of adverse effects and the targeting of multiple signaling pathways addressed by nutritional compound mixtures such as plant extracts (Bjorkman 1999) . A comprehensive review on current nutraceuticals for the management of OA has been published elsewhere (Ameye and Chee 2006) .
Caesalpinia sappan L. (Leguminosae) is distributed in Southeast Asia, and its dried heartwood (also known as Sappan wood) has been a traditional ingredient of food or beverages such as Bir Pletok, a Batavian spice drink. The extract was shown to lack toxic effects and to possess antiatherogenic potential in rats based on its constituent hematein (Sireeratawong et al. 2010; Oh et al. 2001) . In traditional Chinese medicine, Caesalpinia sappan is known to promote blood circulation and to possess analgesic or anti-inflammatory properties (China Pharmacopoeia 2010) . In Japan, Sappan wood was listed in the 15th edition of the Japanese Pharmacopoeia (2006) . A range of constituents including brazilin, hematoxylin, brazilein, photosappanin derivatives, flavones, and other homoisoflavonoids has been isolated from Caesalpinia sappan (Chen et al. 2008; Washiyama et al. 2009; Xie et al. 2000) . Extracts of Caesalpinia sappan as well as some of their defined constituents have been investigated as functional food, revealing potential anti-inflammatory (Jeong et al. 2008) , vasorelaxing (Xie et al. 2000) , immunosuppressive (Ye et al. 2006) , and hepatoprotective effects (Srilakshmi et al. 2010) . At the time of finalizing this manuscript, Sun et al. published a study demonstrating the efficacy of a Caesalpinia sappan extract in an animal model of rheumatoid arthritis (Sun et al. 2011) . Rats treated daily with 1.2, 2.4, or 3.6 g/kg extract showed reduced signs of paw swelling and arthritis severity as well as lower levels of proinflammatory mediators in the plasma as compared to untreated animals. The mechanisms underlying these effects, however, are still not fully understood.
The present study was driven by the hypothesis that the extract of Caesalpinia sappan (CSE) interferes with catabolic processes in human OA chondrocytes. We cultured human chondrocytes in the presence of IL1b and examined the biological effects of CSE co-treatment on the expression and activity of major MMPs. The results presented here demonstrate that CSE strongly inhibits chondrocyte catabolism by suppressing IL1b-induced MMPs mRNA and protein levels. We further present evidence that CSE interferes with MMP-13 promoter activation mediated by NF-kB subunits p50 and p65.
Materials and methods

Preparation and characterization of CSE
The heartwoods of Caesalpinia sappan were collected in June 2006 in San-Pa-Thong district, Chiang Mai province, Thailand, and identified by comparison with the voucher specimen (No. 87-1631) at the Herbarium Section, Northern Research Center for Medicinal Plants, Faculty of Pharmacy, Chiang Mai University, Thailand. Ethanolic extraction was performed by continuously extracting 30 g powdered heartwood in 350 ml 96% EtOH for 24 h using a Soxhlet apparatus. Then, the liquid extract was evaporated under reduced pressure to yield solid CSE. The composition of CSE has been described in detail previously (Chen et al. 2008) . For further characterization, 4 batches of CSE were analyzed qualitatively using HPLC. Briefly, CSE samples were dissolved in MeOH (1 mg/ml), filtrated through a 0.2 lm sterile filter, and analyzed by HPLC (ICS-3000, Dionex, USA) using a Nucleodur C-18 column (Macherey-Nagel, D), a PDA-100 detector (Dionex) and a solvent gradient of MeOH and bidistilled H 2 O (both containing 2.5% acetic acid). At 280 nm, all 4 batches yielded congruent chromatograms which were also comparable to that of the standardized reference Natural Red 24 (MP Biomedicals, USA, LOT #: R25179), a commercially available Sappan wood extract (Supplementary Figure 1) . For cell treatment, CSE was dissolved in 96% EtOH (10 mg/ml) and used in appropriate dilutions for the in vitro assays. The activity of specific components was not addressed in the current study.
Cell culture
Human articular cartilage was obtained from intact regions of femoral condyles and tibial plateaus at the time of total knee replacement surgery in OA patients with informed consent and in accordance with the terms of the ethics committee of the Medical University Vienna (EKNr.: 081/2005). Primary chondrocytes (PCs) were isolated according to standard protocols (Toegel et al. 2009 ), seeded at 10 5 cells/cm 2 , and grown in an atmosphere of humidified 5% CO 2 /95% air at 37°C using Dulbecco's Modified Eagle Medium (DMEM; Gibco, A) supplemented with 10% fetal calf serum (FCS; Biochrom AG, D) and gentamycin (complete medium). Only freshly isolated PCs were used for all assays throughout the study. Human SW1353 chondrosarcoma cells were seeded at 10 4 cells/ cm 2 and maintained in complete medium, whereas T/C28a2 immortalized chondrocytes were seeded at 10 4 cells/cm 2 and cultured using DMEM/F12 containing 10% FCS. Prior to cell treatment, chondrocytes were starved for 6 h in serum-free DMEM containing 2% insulin-transferrin-selenium solution (Gibco, A) (ITS medium). Then, cells were pretreated for 1 h with CSE or vehicle in ITS medium followed by the addition of 10 ng/ml IL1b (Strathmann Biotec, D) and further incubation for the indicated times.
Viability assay
Primary chondrocytes were seeded at 3 9 10 3 cells/well into 96-well microplates (Iwaki, J), serum-starved, and treated in quadruplicate with serial dilutions of CSE for 72 h. Cell proliferation was evaluated using the MTTbased EZ4U cell proliferation assay (Biomedica, A) following the manufacturer's instructions. The experiment was repeated twice with cells from different donors.
Gelatin zymography
Serum-starved cells were cultured in the presence of 5 lg/ ml CSE for 48 h. Ten microliter of cell culture supernatant was mixed with 10 ll Sample buffer (0.5 M TrisHCl, 20% Glycerol, 10% SDS, 0.1% Bromophenol Blue) and incubated for 10 min at room temperature. The samples were loaded on gelatin (1 mg/ml)-containing SDS-polyacrylamide gels for electrophoresis with constant voltage (125 V). After running, the gel was incubated in renaturation buffer (2.5% Triton X-100) with gentle agitation for 30 min at room temperature. Afterward, the gel was equilibrated for 30 min in developing buffer (50 mM Tris-Base, 0.2 M NaCl, 5 mM CaCl2, 0.02% Brij35) and then incubated in fresh developing buffer overnight at 37°C. The zymographic activities were revealed by staining the gel with 0.2% Coomassie Blue. Gels were destained with a destaining solution (7.5% acetic acid in 20% ethanol). Areas of protease activity appeared as clear bands against a dark blue background, where the substrate digestion by the protease occurred. Molecular weights were estimated by comparison with prestained SDS-PAGE markers and a human pro-MMP-2 standard (AnaSpec, USA).
In a different approach, 0.1 lg/ml human pro-MMP-2 (AnaSpec, USA) were mixed with sample buffer and subjected to gelatine zymography as described above. Following electrophoresis, the gel was divided into equal parts, and the individual strips were developed in different developing buffers containing 5 lg/ml CSE, 10 lg/ml CSE, or 1 mM EDTA as positive control, respectively (Albini et al. 2001; Mazzoni et al. 2007 ).
MMP ELISA
Primary human chondrocytes (n = 3 donors) and SW1353 cells were cultured as described in 12-well plates and pretreated with 5 lg/ml CSE followed by the addition of 10 ng/ml IL1b. After 48 h, the culture supernatants were collected, centrifuged, and stored at -80°C. ELISA assays for MMP-2 and MMP-13 were carried out following the protocols provided by the manufacturer (RayBiotech, USA).
Quantitative real-time RT-PCR Primary chondrocytes and SW1353 cells were cultured as described in 12-well plates and pretreated for 1 h with 5 lg/ml CSE followed by the addition of 10 ng/ml IL1b. After 6 h, cell monolayers were washed with PBS and total RNA was extracted using the NucleoSpin RNA II Kit (Macherey-Nagel, D) according to the manufacturer's instructions. On-column DNase digestion was performed for all samples during the isolation process. To quantify and control for the integrity of the isolated RNA preparations, each sample was run on the Agilent 2100 Bioanalyzer Nano LabChip prior to reverse transcription of equal RNA quantities into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, A). RNA integrity numbers (RINs) were found to range from 7.8 to 10 for all samples.
SYBR green-based RT-qPCR assays for MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, and MMP-13 as well as TIMP-1, TIMP-2, and TIMP-3 were established according to previously published protocols (Toegel et al. 2007 (Toegel et al. , 2008 . Details on primer sequences are given in Table 1 . Amplification efficiencies of all primers were evaluated using dilution series of cDNA prepared from chondrocyte mRNA. All RT-qPCR reactions were performed in 25-ll reaction mixtures containing 1 ll cDNA, 12.5 ll SensiMix SYBR Green Master Mix (GenXpress, A), 100 nM primers (Metabion, D), and nuclease-free water to 25 ll and run in duplicate on an Mx3000P QPCR system (Stratagene, USA). Melting curves were generated to confirm a single gene-specific peak and no-template-controls were included in each run to control for contaminations.
The regulation of target genes was calculated as quantities relative to the untreated control group using the MxPro real-time QPCR software, considering both amplification efficiencies and normalization to GAPDH as reference gene. In preceding experiments, the expression stability of 5 candidate reference genes (GAPDH, ACTB, HPRT1, SDHA, B2M) was determined in human chondrocytes and SW1353 cells treated with 5, 10, and 20 lg/ ml CSE, as described above. Then, the expression stabilities were evaluated using the geNorm software (Vandesompele et al. 2002) , and GAPDH was selected as stable reference gene under the experimental conditions of this study.
We declare that the current study has adhered to the minimal guidelines for the design and documentation of qPCR experiments as recently outlined by Bustin et al. (2010) . A qPCR checklist listing all relevant technical information has been provided for the reviewers to assess the technical adequacy of the used qPCR protocols (Supplementary Table 1 ).
Transfection and reporter assays
The MMP-13 promoter sequence spanning -1007/?27 bp of the human MMP13 promoter was prepared by PCR and cloned into the pGL2-Basic luciferase reporter vector (Promega; USA) as previously described (Ijiri et al. 2005) . The expression vectors encoding the NF-kB p50 and p65 subunits were previously described (Grall et al. 2005) . The sequences of all constructs were confirmed by DNA sequencing.
Transient transfection experiments were carried out in T/C-28a2 cells using LipofectAMINE PLUS TM Reagents (Invitrogen; USA). Cells were seeded in 24-well tissue culture plates and cultured to 80% confluence. Transfections were carried out in serum-free antibiotic-free medium using no more than 325 ng of plasmid DNA, including 300 ng of reporter constructs and 25 ng of expression vectors or pCI empty vector (control). After incubation for 1 h at 37°C with the transfection mixture, cells were treated with 1 ml of serum-free medium containing CSE or caffeic acid phenethyl ester (CAPE; Calbiochem, D) and incubation was continued for 23 h. Cell lysates were prepared using the Reporter Lysis Buffer (Promega), and luciferase activities were determined by chemiluminescence assay using the LMaxII384 luminometer (Molecular Devices, USA) and the Luciferase Assay Substrate (Promega). Data are representative of two independent experiments performed in triplicate and expressed as fold change versus control. Statistics Data were exported to the GraphPad Prism statistics software package (GraphPad Prism Software, USA). The Gaussian distribution of the data was verified using the KolmogorovSmirnov test. Statistics were performed using one-way analysis of variance (ANOVA) with post hoc Tukey tests, cross-comparing all study groups (95% confidence interval). P-values \0.05 were considered significant.
Results
Cytotoxicity
Aiming to test the potential use of CSE as MMP inhibitor in chondrocytes, we first evaluated the cytotoxic effects of the extract on primary human chondrocytes using an MTTbased viability assay. As shown in Fig. 1 , CSE concentrations up to 20 lg/ml did not induce cytotoxicity in chondrocytes, whereas 40 lg/ml CSE significantly reduced viability (47.0 ± 2.2%). In the subsequent assays, therefore, we used the concentrations of CSE below 20 lg/ml.
CSE does not directly modify gelatinolytic activities
Previous work has suggested that MMP-2 is involved in both the physiological collagen turnover in articular cartilage and the matrix degradation in OA cartilage (Duerr et al. 2004) . Using gelatin zymography, the present study confirms that chondrocytes isolated from OA cartilage, as well as SW1353 cells (data not shown), express functional pro-MMP-2 (Fig. 2a) . In contrast, bands corresponding to MMP-9 activity were hardly detectable (data not shown), reflecting the differences in MMP-2 and MMP-9 mRNA levels ( Table 2 ). The images also indicate that the activity of MMP2 was not affected in primary chondrocytes treated with 5 lg/ml CSE (Fig. 2a) . Similarly, when added to the buffer during zymography development, CSE did not substantially affect the enzymatic activity of recombinant MMP-2, whereas the addition of EDTA completely abrogated the gelatinolytic activity (Fig. 2b) .
CSE inhibits IL1b -stimulated production of MMP-13
In order to investigate the effect of CSE on MMP-13 and MMP-2 protein levels produced by human chondrocytes, supernatants of treated cell cultures were collected and subjected to ELISA. We observed that neither IL1b nor CSE significantly modified the expression of MMP-2 in primary or SW1353 cells (data not shown). In contrast, MMP-13 levels were significantly up-regulated in both SW1353 and primary cells after treatment with IL1b (Fig. 3) . Pretreatment of SW1353 cells with 5 lg/ml CSE significantly reduced IL1b-stimulated MMP-13 production from 6.7 ± 1.6 to 2.5 ± 1.4 pg/ml, which was comparable to the levels found in untreated cells (1.2 ± 0.5 pg/ml; P [ 0.05). In primary chondrocytes, CSE significantly reduced IL1b-stimulated MMP-13 levels from 16.3 ± 1.4 to 13.1 ± 2.7 pg/ml (P \ 0.05; n = 3 donors). a Cell culture supernatants of primary chondrocytes isolated from 2 patients (PC1 and PC2) were treated and subjected to gelatine zymography as described in Materials and Methods. Lane 1 shows the activity of a recombinant human pro-MMP-2. Lanes 2 and 4 show the supernatants of untreated chondrocytes, whereas lanes 3 and 5 present the supernatants of the chondrocytes treated with 5 lg/ ml CSE, respectively. b Recombinant human pro-MMP-2 was subjected to gelatine zymography and developed separately in different developing buffers containing 5 lg/ml CSE, 10 lg/ml CSE or 1 mM EDTA Genes Nutr (2012) 7:307-318 311
CSE inhibits gene expression of MMPs, but not of TIMPs
To evaluate the effects of CSE on MMP and TIMP expression in human chondrocytes, mRNA levels of 7 MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13) and 3 TIMPs (TIMP-1, TIMP-2, TIMP-3) were quantified using RT-qPCR (Table 2 ). In agreement with previous reports (Fan et al. 2005 ), MMP-3 was the most abundant (12.1 ± 12.2 molecules/molecules GAP-DH) of the MMPs analyzed in human OA primary chondrocytes, with MMP-7 and MMP-8 showing the lower expression levels. The expression levels of TIMP-1, TIMP-2, and TIMP-3 were relatively higher compared with most MMPs, with lower expression of TIMP-3 (Table 2) . Interestingly, the SW1353 cell line showed a different MMP and TIMP expression profile as compared to primary cells (Table 2) , with MMP-2 being the most abundant (0.22 molecules/molecule GAPDH) and very low levels of MMP-1, MMP-3, and MMP-13 mRNA. IL1b up-regulated the expression of a number of MMPs in SW1353 cells, including MMP-1 (Fig. 4a, 64 .0 ± 3.1 fold), MMP-3 (Fig. 4c, 27 .4 ± 0.8 fold), MMP-7 (Fig. 4d, 3 .2 ± 0.1 fold), MMP-8 (Fig. 4e, 6 .3 ± 1.1 fold), MMP-9 (Fig. 4f,  1 .8 ± 0.1 fold), and MMP-13 (Fig. 4g, 71 .4 ± 1.1 fold). Preincubation of SW1353 cells with CSE suppressed the IL1b-induced mRNA levels of these MMPs in a dosedependent manner. Of note, 5 lg/ml CSE strongly inhibited the expression of MMP-1 (Fig. 4a) , MMP-3 (Fig. 4c) , and MMP-13 (Fig. 4g) mRNA as compared to IL1b-treated cells (P \ 0.05), and 10 lg/ml CSE further down-regulated the expression of these genes to levels comparable to control cells (P [ 0.05). In addition, 5 lg/ml of CSE reduced the IL-1b-induced MMP-7 (Fig. 4d) , MMP-8 (Fig. 4e) , and MMP-9 (Fig. 4f) expression to basal levels. Regarding MMP-2 gene expression, no alterations were observed in SW1353 cells under the experimental conditions of this study (Fig. 4b) .
In keeping with those observations, the results obtained with human OA primary chondrocytes (n = 3; PC1,2,3) further confirmed those obtained in SW1353 cells, as shown in Table 3 . Namely, despite minor inter-individual differences, IL1b significantly increased mRNA levels of MMP-1, MMP-3, MMP-7, MMP-9, and MMP-13 in all 3 cell populations. At 5 lg/ml, CSE significantly suppressed the IL1b-mediated upregulation of MMP-3, MMP-7, MMP-9, and MMP-13 in all cell populations and that of MMP-1 in 2 out of 3 donors. Similar to the results in SW1353 cells, mRNA levels were quantified using RT-qPCR and expressed as number of molecules per molecules of GAPDH. Articular chondrocytes were isolated from cartilage specimens of 3 donors (PC1, PC2, PC3) and cultured and analyzed separately. Mean values and standard deviations (SD) of the 3 primary cell populations are also presented Fig. 3 CSE inhibits IL1b-stimulated MMP-13 production in human chondrocytes. Primary chondrocytes (PC) were isolated from 3 donors and cultured and analyzed separately. Serum-starved SW1353 cells and PC were pretreated with 5 lg/ml CSE followed by the coincubation with 10 ng/ml IL1b for 48 h. MMP-13 concentration was determined in the cell culture supernatants using ELISA. Mean values and standard deviations from 2 independent experiments (SW1353) and from 3 donors (PC) are given. *indicates significant differences with respect to cells treated with IL1b only (P \ 0.05).
# indicates significant differences with respect to untreated controls (P \ 0.05) 10 and 20 lg/ml CSE reduced the IL-1b-induced MMP mRNA expression to basal levels. Expression of MMP-2 and MMP-8 were only slightly altered in the presence of IL1b and CSE (P \ 0.05 in 1 out of 3 donors).
Since the balance between MMP and TIMP activities determines cartilage degradation in OA [Nagase and Woessner 1999) , we examined the effect of 5 lg/ml CSE on the gene expression of TIMP-1, TIMP-2, and TIMP-3 in IL1b-treated chondrocytes (Fig. 5) . In primary cells, neither IL1b nor 5 lg/ml CSE regulated the mRNA levels of any of the TIMPs (Fig. 5a, b, c) . In SW1353 cells, however, TIMP-1 and TIMP-3 mRNA levels were up-regulated by IL1b 2.1 ± 0.3 fold and 3.0 ± 0.1 fold, respectively. Treatment with 5 lg/ml CSE reduced only TIMP-3 mRNA levels significantly in SW1353 cells (Fig. 5d) .
These results suggest that CSE is a potent inhibitor of IL1b-mediated MMP transcription in human chondrocytes, whereas it appears not to interfere with TIMP gene expression.
CSE inhibits MMP-13 promoter activation
It has been shown that IL1b-induced MMP gene expression is mediated by diverse signaling pathways and transcription Fig. 4 CSE inhibits IL1b-mediated MMP transcription in SW1353 cells. Serum-starved SW1353 cells were pretreated with 5, 10, or 20 lg/ml of CSE followed by the addition of 10 ng/ml IL1b. After 6 h of incubation, total RNA was isolated and mRNA levels of a MMP-1, b MMP-2, c MMP-3, d MMP-7, e MMP-8, f MMP-9, and g MMP-13 were quantified using RT-qPCR and expressed as fold change with respect to untreated controls. Mean values and standard deviations are given. *indicates significant differences with respect to cells treated with IL1b only (P \ 0.05).
# indicates significant differences with respect to untreated controls (P \ 0.05) Genes Nutr (2012) 7:307-318 313 factors, including NF-kB (Vincenti and Brinckerhoff 2002; Marcu et al. 2010) . To further explore the mechanism underlying suppression of MMP transcription by CSE, human T/C-28a2 chondrocytes were co-transfected with a MMP-13 reporter construct and p65/p50 expression vectors in the presence or absence of CSE. As shown in Fig. 6 , p65/p50 overexpression transactivated the pGL2B(-1007/?27)MMP-13 construct by 7.1 ± 1.5 fold, and CSE reversed the p65/p50-driven MMP-13 promoter transactivation in a concentration-dependent manner. Whereas 5 lg/ml CSE significantly inhibited MMP-13 promoter activity by about 65%, 10 lg/ml CSE completely blocked the p65/p50-mediated promoter activation, re-establishing levels comparable to those in the untreated control (P [ 0.05). For comparison, additional experiments using CAPE were performed (Fig. 6) . CAPE dose-dependently reduced the p65/p50-dependent promoter activation at a concentration of 0.5 lg/ml (P \ 0.05) and re-established control levels at 2.5 lg/ml.
Discussion
The present study shows for the first time that CSE inhibits MMP expression in human chondrocytes in vitro. As our data demonstrate, pretreatment of primary chondrocytes with CSE effectively suppressed the IL1b-mediated upregulation of MMP-1, MMP-3, MMP-7, MMP-9, and MMP-13 at the level of gene expression involving NFkB signaling.
Since exacerbated production and activation of MMPs is associated with rheumatoid arthritis and OA, MMPs represent promising pharmacological targets for the treatment of arthritic diseases (Jacobsen et al. 2010) . Strategies for MMP inhibition include direct MMP inhibition (by TIMPs, small molecule MMP inhibitors, or antibodies) and indirect MMP inhibition targeting signaling pathways that lead to MMP expression. Although considerable progress has been made in the development of direct MMP inhibitors, severe off-target effects, poor bioavailability and efficacy are frequently associated with their use in clinical trials ?CSE 5 lg/ml ?CSE 10 lg/ml ?CSE 20 lg/ml MMP-1 PC1 1.00 ± 0.10 5.76 ± 0.26* 1.83 ± 0.03** 0.91 ± 0.07** 0.78 ± 0.06** PC2 1.00 ± 0.18 15.4 ± 0.01* 10.12 ± 0.45** 2.21 ± 0.22** 0.91 ± 0.10** PC3 1.00 ± 0.15 4.24 ± 0.28* 3.63 ± 0.18 3.10 ± 0.06** 1.27 ± 0.09** MMP-2 PC1 1.00 ± 0.06 1.46 ± 0.06* 1.05 ± 0.09** 0.97 ± 0.05** 0.83 ± 0.02** PC2 1.00 ± 0.02 1.17 ± 0.05 1.08 ± 0.15 1.06 ± 0.13 0.82 ± 0.02 PC3 1.00 ± 0.09 1.24 ± 0.03 1.23 ± 0.04 1.55 ± 0.08** 1.06 ± 0.08 MMP-3 PC1 1.00 ± 0.01 3.16 ± 0.01* 1.35 ± 0.02** 1.08 ± 0.01** 0.84 ± 0.01** PC2
1.00 ± 0.01 8.37 ± 0.25* 3.71 ± 0.09** 1.12 ± 0.01** 1.05 ± 0.04** PC3 1.00 ± 0.01 4.74 ± 0.02* 3.12 ± 0.02** 3.48 ± 0.02** 1.15 ± 0.01** MMP-7 PC1 1.00 ± 0.46 10.40 ± 1.06* 5.56 ± 0.92** 1.97 ± 1.60** 3.41 ± 0.02** PC2 1.00 ± 0.47 8.19 ± 0.26* 2.41 ± 0.27** 3.15 ± 1.33** 2.14 ± 0.82** PC3 1.00 ± 0.19 4.45 ± 0.17* 3.02 ± 0.12** 2.78 ± 0.06** 3.04 ± 0.11** MMP-8 PC1 1.00 ± 0.57 1.29 ± 0.02 1.92 ± 0.22 0.65 ± 0.35 1.32 ± 0.58 PC2 1.00 ± 0.06 2.11 ± 0.33* 1.69 ± 0.35 1.02 ± 0.02** 0.57 ± 0.11** PC3 1.00 ± 0.02 1.44 ± 0.13 1.14 ± 0.03 2.04 ± 0.26 0.89 ± 0.17 MMP-9 PC1 1.00 ± 0.01 1.89 ± 0.28* 1.11 ± 0.04** 0.85 ± 0.16** 1.03 ± 0.10** PC2 1.00 ± 0.04 10.29 ± 1.28* 2.64 ± 0.36** 0.66 ± 0.16** 0.54 ± 0.06** PC3 1.00 ± 0.37 7.65 ± 1.48* 3.76 ± 1.15** 1.22 ± 0.14** 2.15 ± 0.18** MMP-13 PC1 1.00 ± 0.17 13.22 ± 0.07* 1.39 ± 0.03** 0.72 ± 0.04** 0.64 ± 0.05** PC2 1.00 ± 0.01 10.42 ± 0.37* 2.71 ± 0.23** 1.11 ± 0.03** 0.85 ± 0.01** PC3 1.00 ± 0.02 4.65 ± 0.40* 2.80 ± 0.24** 4.42 ± 0.54 1.20 ± 0.01** Primary chondrocytes were isolated from 3 donors (PC1, PC2, PC3) and cultured and analyzed separately. Serum-starved cells were pretreated with 5 to 20 lg/ml CSE followed by stimulation with 10 ng/ml IL1b for 6 h. mRNA levels of MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-13 were quantified using RT-qPCR and expressed as fold change with respect to untreated controls. Mean values and standard deviations are given. * indicates significant differences with respect to untreated controls (P \ 0.05). ** indicates significant differences with respect to cells treated with IL1b only (P \ 0.05) (Clutterbuck et al. 2009 ). Thus, indirect MMP inhibition using nutraceuticals or plant-derived phytopharmaceuticals might provide a promising alternative to present therapeutic approaches. In this context, curcumin, resveratrol, or green tea catechins have already been investigated regarding their MMP-inhibitory actions (Shakibaei et al. 2007; Lee and Moon 2005; Annabi et al. 2007 ).
The results presented here suggest that Caesalpinia sappan-derived phytochemicals might be developed as nutraceuticals for the management of arthritic diseases. In this context, the strong inhibitory action of CSE on the IL1b-mediated overexpression of MMP-1, MMP-3, and MMP-13 appears of particular interest. Exacerbated production and activation of the collagenases, MMP-1 and ) and cultured and analyzed separately. Serum-starved cells were pretreated with 5 lg/ ml CSE followed by the addition of 10 ng/ml IL1b. After 6 h of incubation, the mRNA levels of TIMP-1 (a), TIMP-2 (b), and TIMP-3 (c) were quantified using RT-qPCR and expressed as fold change with respect to untreated controls (white bars). Gray bars represent IL1b-treated cells, whereas black bars represent cells pretreated with CSE. d TIMP-1, TIMP-2, and TIMP-3 mRNA levels were quantified in SW1353 cells under exposure to IL1b and CSE as described. Mean values and standard deviations are given. *indicates significant differences with respect to cells treated with IL1b only (P \ 0.05).
# indicates significant differences with respect to untreated controls (P \ 0.05) Fig. 6 Effect of CSE or CAPE on MMP-13 promoter activity. T/C28a2 chondrocytes, cotransfected with a MMP-13 luciferase reporter construct and p50 and p65 expression vectors, were treated with CAPE (gray bars) or CSE (black bars) in a dose-dependent manner. Both CAPE and CES inhibited the NF-kB(p65/p50)-driven MMP-13 promoter activation.
# indicates significant differences with respect to cells transfected with the MMP-13 reporter construct and the pCI empty vector (P \ 0.05). *indicates significant differences with respect to cells co-transfected with the MMP-13 promoter and the p65/p50 expression vectors (P \ 0.05) MMP-13, in articular chondrocytes are known to promote the cleavage of collagen triple helices allowing further degradation by other MMPs (Nagase and Woessner 1999) . Supporting the role of MMP-13 in connective tissue degradation, Neuhold et al. (2001) reported that transgenic mice overexpressing MMP-13 show signs of articular cartilage degradation and exhibit joint pathology similar to that found in OA. Our results confirm that IL1b represents a potent inflammatory stimulus that leads to overexpression of MMP-1, MMP-3, and MMP-13 mRNA in primary and SW1353 chondrocytes. Interestingly, the upregulation of these genes by IL1b was more pronounced in SW1353 cells than in primary OA chondrocytes; however, when cultured in the presence of 5-20 lg/ml CSE, the effect of IL1b was suppressed in both cell models and the expression of MMP-1, MMP-3, and MMP-13 mRNA was downregulated to levels found under control conditions. The relevance of the RT-qPCR data was further verified by ELISA, demonstrating reduced MMP-13 protein levels in chondrocytes treated with CSE. In contrast, however, the transcription of TIMPs was not affected by the presence of CSE. Of note, CSE treatment did not totally block the expression of MMPs but rather inhibited IL1b-induced MMP overexpression. In this regard, CSE might be advantageous over other MMP inhibitors, since total MMP inhibition not only impairs physiological ECM remodeling, but may also affect cellular signaling to which MMPs contribute (Clutterbuck et al. 2009 ). In this context, it is noteworthy that CSE did not directly influence the gelatinolytic activity of MMP-2 under the experimental conditions of this study.
In a first attempt to elaborate the mechanism underlying the MMP-inhibitory action of CSE, we focused on the role of NF-kB in MMP-13 promoter activation. It is well established that IL1b, once bound to its type 1 receptor, activates NF-kB dimers by triggering phosphorylation and subsequent degradation of the inhibitory kB proteins (Daheshia and Yao 2008) . The most prevalent activated NF-kB dimer is the heterodimer RelA (p65)/p50, which can bind to sites in NF-kB-dependent promoters regulating the transcription of response genes (Roman-Blas and Jimenez 2006). Mengshol et al. have assessed the role of NF-kB in MMP-13 transcription in chondrocytes and found that, besides JNK and p38, NF-kB signaling is required for the IL1b-mediated induction of MMP-13 (Mengshol et al. 2000) . Although the promoter of MMP-13 does not contain consensus NF-kB binding sites (Burrage et al. 2006) , the link between NF-kB activation and MMP-13 induction has been further demonstrated in a previous study on the effect of hyaluronan oligosaccharides in articular chondrocytes (Ohno et al. 2006) . We show here that, indeed, NF-kB p65/p50 overexpression leads to MMP-13 promoter transactivation and that CSE suppresses the p65/p50-driven MMP-13 promoter activation, thereby suggesting that CSE's MMP-inhibitory actions are related to its blockade of the NF-kB signaling. Furthermore, the comparison to CAPE, a chemically defined specific inhibitor of NF-kB (Natarajan et al. 1996) , revealed that CSE was only about 4 times less active in our assay. Our results go along with previous reports demonstrating that CSE and its constituents interfere with NF-kB signaling in different cell types. Namely, Bae et al. (2005) showed that brazilin, the main component of CSE, inhibited the DNA binding activity of NF-kB and AP-1 in LPS-stimulated mouse macrophages. In addition, protosappanin A was shown to target the NF-kB pathway in rat heart tissue (Wu et al. 2010) . Therefore, our results suggest that CSE contains one or more active components that may act as potent inhibitors of NF-kB in human chondrocytes.
To date, the bioavailability of specific components of CSE has not been elaborated and it remains elusive whether the doses of CSE used in this study are representative for physiologically active concentrations. Despite this lack of specific knowledge, the efficacy of CSE in diverse in vivo models supports the apparent bioavailability of CSE components at therapeutically effective doses (Sun et al. 2011; Oh et al. 2001) . Moreover, the present study demonstrates that CSE affects human chondrocytes in vitro at concentrations that are comparable to those of well-known dietary antioxidants including ascorbic acid, curcumin, or resveratrol (Csaki et al. 2009; Graeser et al. 2009 ). Similar to curcumin and resveratrol, CSE appears to exert its effects on chondrocytes via mechanisms targeting NFkB signaling. Interestingly, recent data have explored the different molecular targets of curcumin and resveratrol as well as their synergistic chondroprotective effects (Csaki et al. 2009 ). In this context, it might be of interest to further investigate the synergism between CSE components and other dietary antioxidants regarding the modulation of biomarkers of inflammation in cultured chondrocytes.
Conclusion
In summary, this study suggests that CSE or CSE-derived compounds may be beneficial as indirect MMP inhibitors for the future management of degenerative or inflammatory joint diseases. We present evidence that CSE effectively suppresses IL1b-mediated overexpression of major MMPs in human chondrocytes in vitro. More specifically, CSE inhibits the de novo synthesis of MMP-1, MMP-3, MMP-7, MMP-9, and MMP-13 at the gene expression level without affecting the expression of TIMPs. Further, we showed that the molecular mechanism underlying MMP-13 inhibition by CSE involves, at least in part, the interference with the NF-kB (p65/p50)-driven MMP-13 promoter transactivation. Future studies should therefore aim to define CSE's actions in the context of arthritic diseases and to further delineate the molecular mechanisms evoked by CSE and its specific constituents both in vitro and in vivo.
